Rationale and approaches to phosphate and fibroblast growth factor 23 reduction in CKD

Tamara Isakova*, Joachim H. Ix, Stuart M. Sprague, Kalani L. Raphael, Linda Fried, Jennifer J. Gassman, Dominic Raj, Alfred K. Cheung, John W. Kusek, Michael F. Flessner, Myles Wolf, Geoffrey A. Block

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

115 Scopus citations


Patients with CKD often progress to ESRD and develop cardiovascular disease (CVD), yet available therapies only modestly improve clinical outcomes. Observational studies report independent associations between elevated serumphosphate and fibroblast growth factor 23 (FGF23) levels and risks of ESRD, CVD, and death. Phosphate excess induces arterial calcification, and although elevated FGF23 helps maintain serum phosphate levels in the normal range in CKD, it may contribute mechanistically to left ventricular hypertrophy (LVH). Consistent epidemiologic and experimental findings suggest the need to test therapeutic approaches that lower phosphate and FGF23 in CKD. Dietary phosphate absorption is one modifiable determinant of serum phosphate and FGF23 levels. Limited data from pilot studies in patients with CKD stages 3-4 suggest that phosphate binders, low phosphate diets, or vitamin B3 derivatives, such as niacin or nicotinamide, may reduce dietary phosphate absorption and serum phosphate and FGF23 levels. This review summarizes current knowledge regarding the deleterious systemic effects of phosphate and FGF23 excess, identifies questions that must be addressed before advancing to a full-scale clinical outcomes trial, and presents a novel therapeutic approach to lower serum phosphate and FGF23 levels that will be tested in the COMBINE Study: The CKD Optimal Management With BInders and NicotinamidE study.

Original languageEnglish (US)
Pages (from-to)2328-2339
Number of pages12
JournalJournal of the American Society of Nephrology
Issue number10
StatePublished - Oct 1 2015

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Rationale and approaches to phosphate and fibroblast growth factor 23 reduction in CKD'. Together they form a unique fingerprint.

Cite this